合計 50 件の最近のインサイダー取引記録が記録されています X4 Pharmaceuticals, Inc. (XFOR), 内訳は 34 件の買い および 12 件の売り. インサイダー買い総額は $16.94M インサイダー売り総額は $474.36K.
最近活動のある主要インサイダーには Wyzga Michael S, Stewart Murray, De Craecker Francoise. インサイダー取引記録は、経営陣が株式の評価と将来の見通しをどう見ているかについての洞察を提供します.
インサイダー取引記録 — XFOR
| 日付 |
氏名 |
役職 |
取引種別 |
株数 |
平均価格 |
価値 |
保有株数 |
| 2026-01-01 |
Wyzga Michael S |
Director |
RSU 付与（制限付株式） |
110,000 |
$4.00 |
$440K |
- |
| 2026-01-01 |
Stewart Murray |
Director |
RSU 付与（制限付株式） |
110,000 |
$4.00 |
$440K |
- |
| 2026-01-01 |
De Craecker Francoise |
Director |
RSU 付与（制限付株式） |
110,000 |
$4.00 |
$440K |
- |
| 2026-01-01 |
Bridger Gary |
Director |
RSU 付与（制限付株式） |
110,000 |
$4.00 |
$440K |
- |
| 2025-10-29 |
Kirske David |
Chief Financial Officer |
RSU 付与（制限付株式） |
1,552,769 |
$1.42 |
$2.2M |
1,552,769 |
| 2025-10-29 |
Craig Adam R |
Executive Chairman |
RSU 付与（制限付株式） |
2,329,154 |
$1.42 |
$3.31M |
2,329,154 |
| 2025-10-29 |
Volpone John |
President |
RSU 付与（制限付株式） |
2,329,154 |
$1.42 |
$3.31M |
2,329,154 |
| 2025-10-23 |
Craig Adam R |
Executive Chairman |
情報に基づく買い |
86,206 |
$2.90 |
$250K |
376,087 |
| 2025-08-14 |
Kirske David |
Chief Financial Officer |
RSU 付与（制限付株式） |
193,254 |
- |
- |
193,254 |
| 2025-08-14 |
Craig Adam R |
Executive Chairman |
RSU 付与（制限付株式） |
289,881 |
- |
- |
289,881 |
| 2025-08-14 |
Volpone John |
President |
RSU 付与（制限付株式） |
289,881 |
- |
- |
289,881 |
| 2025-08-12 |
Kirske David |
Officer |
不明 |
- |
- |
- |
- |
| 2025-08-12 |
Kirske David |
Chief Financial Officer |
RSU 付与（制限付株式） |
1,073,249 |
$1.42 |
$1.52M |
1,073,249 |
| 2025-08-12 |
Craig Adam R |
Executive Chairman |
不明 |
- |
- |
- |
- |
| 2025-08-12 |
Craig Adam R |
Executive Chairman |
RSU 付与（制限付株式） |
1,609,873 |
$1.42 |
$2.29M |
1,609,873 |
| 2025-08-12 |
Volpone John |
Officer |
不明 |
- |
- |
- |
- |
| 2025-08-12 |
Volpone John |
President |
RSU 付与（制限付株式） |
1,609,873 |
$1.42 |
$2.29M |
1,609,873 |
| 2025-06-09 |
Wyzga Michael S |
Director |
RSU 付与（制限付株式） |
1,500 |
- |
- |
5,555 |
| 2025-06-09 |
Mcgirr David W J |
Director |
RSU 付与（制限付株式） |
1,500 |
- |
- |
4,722 |
| 2025-06-09 |
Bridger Gary |
Director |
RSU 付与（制限付株式） |
1,500 |
- |
- |
4,722 |
| 2025-06-09 |
Stewart Murray |
Director |
RSU 付与（制限付株式） |
1,500 |
- |
- |
7,883 |
| 2025-06-09 |
De Craecker Francoise |
Director |
RSU 付与（制限付株式） |
1,500 |
- |
- |
4,722 |
| 2025-06-09 |
Woods Keith |
Director |
RSU 付与（制限付株式） |
1,500 |
- |
- |
6,000 |
| 2025-05-20 |
Thoren Natasha Fay |
Chief Legal Officer |
不明 |
8,166 |
$32.70 |
$267.03K |
- |
| 2025-05-20 |
Thoren Natasha Fay |
Chief Legal Officer |
RSU 付与（制限付株式） |
3,333 |
- |
- |
9,462 |
| 2025-05-16 |
Baldry Mark |
Chief Commercial Officer |
情報に基づく買い |
1,032 |
$2.48 |
$2.56K |
25,337 |
| 2025-05-16 |
Baldry Mark |
Chief Commercial Officer |
RSU 付与（制限付株式） |
1,032 |
$2.48 |
$2.56K |
25,337 |
| 2025-02-12 |
Baldry Mark |
Chief Commercial Officer |
RSU 付与（制限付株式） |
600,000 |
- |
- |
729,173 |
| 2025-02-12 |
Mostafa Adam S. |
Chief Financial Officer |
RSU 付与（制限付株式） |
850,000 |
- |
- |
850,000 |
| 2025-02-12 |
Ragan Paula |
President and CEO |
RSU 付与（制限付株式） |
2,250,000 |
- |
- |
3,337,386 |
| 2025-02-12 |
Arbet-engels Christophe |
Chief Medical Officer |
RSU 付与（制限付株式） |
850,000 |
- |
- |
864,207 |
| 2025-02-12 |
Dibiase Mary |
Chief Operating Officer |
RSU 付与（制限付株式） |
650,000 |
- |
- |
1,140,980 |
| 2025-01-24 |
Baldry Mark |
Chief Commercial Officer |
情報に基づく売り |
29,159 |
$0.45 |
$13.24K |
94,123 |
| 2025-01-24 |
Mostafa Adam S. |
Chief Financial Officer |
情報に基づく売り |
74,773 |
$0.45 |
$33.95K |
- |
| 2025-01-24 |
Ragan Paula |
President and CEO |
情報に基づく売り |
76,473 |
$0.45 |
$34.72K |
1,087,386 |
| 2025-01-24 |
Arbet-engels Christophe |
Chief Medical Officer |
情報に基づく売り |
11,624 |
$0.45 |
$5.28K |
14,207 |
| 2025-01-24 |
Dibiase Mary |
Chief Operating Officer |
情報に基づく売り |
22,258 |
$0.45 |
$10.09K |
490,980 |
| 2025-01-23 |
Baldry Mark |
Chief Commercial Officer |
RSU 付与（制限付株式） |
74,773 |
- |
- |
123,282 |
| 2025-01-23 |
Mostafa Adam S. |
Chief Financial Officer |
RSU 付与（制限付株式） |
74,773 |
- |
- |
74,773 |
| 2025-01-23 |
Ragan Paula |
President and CEO |
RSU 付与（制限付株式） |
169,940 |
- |
- |
1,163,859 |
| 2025-01-23 |
Arbet-engels Christophe |
Chief Medical Officer |
RSU 付与（制限付株式） |
25,831 |
- |
- |
25,831 |
| 2025-01-23 |
Dibiase Mary |
Chief Operating Officer |
RSU 付与（制限付株式） |
61,178 |
- |
- |
513,238 |
| 2024-11-15 |
Baldry Mark |
Chief Commercial Officer |
情報に基づく買い |
13,404 |
$0.34 |
$4.6K |
129,173 |
| 2024-11-15 |
Ragan Paula |
President and CEO |
情報に基づく売り |
31,897 |
$0.39 |
$12.58K |
993,919 |
| 2024-10-15 |
Ragan Paula |
President and CEO |
情報に基づく売り |
31,897 |
$0.56 |
$17.93K |
1,025,816 |
| 2024-10-07 |
Baldry Mark |
Chief Commercial Officer |
情報に基づく売り |
11,127 |
$0.58 |
$6.51K |
48,509 |
| 2024-10-07 |
Mostafa Adam S. |
Chief Financial Officer |
情報に基づく売り |
230,645 |
$0.55 |
$126.9K |
- |
| 2024-10-07 |
Ragan Paula |
President and CEO |
情報に基づく売り |
239,436 |
$0.55 |
$131.52K |
1,057,713 |
| 2024-10-07 |
Taveras Arthur |
Chief Scientific Officer |
情報に基づく売り |
76,920 |
$0.56 |
$43.31K |
388,026 |
| 2024-10-07 |
Dibiase Mary |
Chief Operating Officer |
情報に基づく売り |
67,695 |
$0.57 |
$38.33K |
452,060 |
■ 情報付き — 公開市場取引（最も重要）
■ 情報なし（買い） — 報酬・オプション行使・転換
■ 情報なし（売り） — 源泉徴収・付与売却
■ 中立 — 贈与・信託・失効
